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Background: Anemia is a prevalent condition in critically ill patients and red blood cell transfusions are frequent.
Although transfusions at low hemoglobin levels have been shown to be associated with equivalent or better
outcomes than higher hemoglobin thresholds, clinical equipoise persists in patients with traumatic brain injury
considering their susceptibility to secondary cerebral insults such as those from hypoxemia.
Methods: Our objectives are to estimate the frequency of red blood cell transfusion in patients with traumatic
brain injury and to evaluate transfusion thresholds, determinants and outcomes associated with transfusion
strategies.
We will conduct a systematic review of cohort studies and randomized controlled trials of patients with traumatic
brain injury. We will search MEDLINE, Embase, BIOSIS and the Cochrane Library for eligible studies. Two
independent reviewers will screen all identified references. Studies including adult patients with traumatic brain
injury reporting data on red blood cell transfusions will be eligible. We will collect data on baseline demographics,
trauma characteristics, hemoglobin thresholds, blood transfusions and clinical outcomes (mortality, length of stay,
complications, and so on). Two independent reviewers will extract data using a standardized form. We will pool
cumulative incidences using DerSimonian and Lair random-effect models after a Freeman-Tukey transformation to
stabilize variances. We will pool risk ratios or mean differences with random-effect models and Mantel-Haenszel or
inverse variance methods in order to evaluate the association between red blood cell transfusion and potential
determinants or outcomes. Sensitivity and subgroup analysis according to timing of red blood cell transfusion,
traumatic brain injury severity, year of conduction of the study, risk of bias, notably, are planned.
Discussion: We expect to observe high heterogeneity in the proportion of transfused patients across studies and
that the global proportion will be similar to the frequency observed in the general medical critically ill population.
Our systematic review will allow us to better describe and understand current transfusion practices in patients with
traumatic brain injury, a clinical population in which liberal transfusions are still advocated in the absence of
evidence-based data.
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Table 1 Structured question
Population • adult patients with traumatic brain injury
Intervention • red blood cell transfusion
Comparator • no transfusion
Primary
outcome




• number of red blood cell units transfused
• determinants of red blood cell transfusion
• mortality
• frequency of withdrawal of life-sustaining therapy
• frequency of unfavourable neurological outcome
• ICU and hospital length of stay
• all other reported clinical outcomes
Study design • cohort studies (both prospective and retrospective)
and randomized controlled trials
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Red blood cell transfusion is a core topic in critical care
medicine. Transfusion practices in the overall non-
bleeding medical and surgical intensive care population
have been extensively described [1,2]. Studies have eval-
uated hemoglobin thresholds for transfusion in critically
ill patients [3-13] and have shown that restrictive trans-
fusion strategies (hemoglobin thresholds between 7 and
9 g/dL) are as safe as liberal strategies (thresholds be-
tween 9 and 12 g/dL) [3,4]. However, specific patient
populations, such as neurocritically ill patients, were un-
derrepresented in these studies and results could thus
not be applied to them. Indeed, given the vulnerability of
the brain to secondary hypoxic insults, concerns have
been raised regarding the safety and efficacy of restrict-
ive transfusion strategies in the presence of traumatic
brain injuries [14]. Two recent guidelines in a neurocriti-
cally ill patient population (subarachnoid hemorrhage)
were published; one recommending to treat anemia but
noting that thresholds were to be determined, and the
other recommending transfusion in order to reach
hemoglobin levels of 80 to 100 g/L [15,16]. Interestingly,
guidelines for the management of patients with trau-
matic brain injury did not cover the topic [17]. A recent
systematic review highlighted the paucity of data regard-
ing the adoption of liberal or restrictive strategies in this
specific population [18] and no consensus has been
reached on appropriate transfusion thresholds [19]. Con-
sidering the high mortality in critically ill patients with
traumatic brain injury [20], the potential impact of red
blood cells transfusion on clinical outcomes and the un-
certainty regarding optimal transfusion strategies in pa-
tients with acute neurologic lesions, current transfusion
practices must be described in order to inform future
clinical trials evaluating transfusion strategies in this
population.
Objectives
We first aim to evaluate current practices regarding red
blood cell transfusion in critically ill patients with trau-
matic brain injuries by estimating the frequency of red
blood cell transfusion in these patients. Secondly, we
seek to evaluate transfusion thresholds, determinants
and outcomes associated with transfusion strategies.
Methods
We propose to conduct a systematic review of cohort
studies and randomized control trials reporting transfu-
sions in patients with traumatic brain injury during their
acute hospital stay.
Protocol and registration
The protocol of the review is registered in PROSPERO
(www.crd.york.ac.uk/prospero) CRD42014007402.Study design
We will conduct a systematic review in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [21] and The
Cochrane Handbook for Systematic Reviews of Interven-
tions [22] methodological recommendations.
Eligibility criteria
Since we are interested in the frequency of red blood cell
transfusion and its determinants, our systematic review
will include prospective and retrospective cohort studies,
and randomized controlled trials. Patients suffering from
a traumatic brain lesion (any severity) will be considered.
In case of a mixed population, at least 80% of patients
included in a specific study have to respect this criterion
for the study to be eligible. Since we expect that few
studies will report precisely if patients were recruited at
hospital admission or intensive care unit (ICU) admis-
sion, we will not restrict inclusion to critically ill patients
but rather consider a population-based approach of
acute care hospital admissions. Studies and trials will
have to report data on red blood cell transfusion fre-
quency. Studies who specifically studied patients with
blood disorders and coagulopathies will be excluded.
Table 1 and Table 2 present the structured study ques-
tion and inclusion and exclusion criteria, respectively.
Information sources
We will systematically search MEDLINE, Embase, BIO-
SIS and The Cochrane Library (from their inception up
to a maximum of nine months before submission for
publication) for eligible studies. References of included
articles and abstracts of major conferences will be
screened to identify additional potentially eligible stud-
ies. Experts in neurocritical care medicine, not members
Table 2 Study eligibility criteria
Inclusion
criteria
• Prospective study, retrospective cohort study or
randomized controlled trials
• Acute setting
• At least 80% of patients suffering from an acute
TRAUMATIC brain lesion
• At least 80% of adults patients (≥18 years old)
• Data on red blood cell transfusion reported
Exclusion
criteria
• Sample of patients with congenital hereditary blood
disorders (example: sickle cell disease, β-thalassemia)
• Sample of patients with coagulation disorders (example:
hemophilia, thrombotic thrombocytopenic purpura,
Von Willebrand disease)
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ongoing studies. We will request available transfusion
data from investigators of retrieved studies if deemed
necessary.
Search strategy
Our search strategy will be based on keywords related to
transfusion and anemia, as well as traumatic brain injury.
Clinicians, investigators with expertise in transfusion or in
neurocritical care, and information specialists will be con-
sulted to verify the search strategy, identify synonyms and
additional search terms. Relevant index terms (Medical
Subject Headings and Emtree) will be added to the strategy.
The search will be limited to human studies [22]. No lan-
guage or date of publication restriction will be used. The
search strategy will be first designed for Medline and
Embase, and will be adapted for other electronic databases
afterwards. The current version of our Medline search
strategy is presented in Additional file 1. This preliminary
strategy has been tested through an iterative process in
order to achieve sufficient specificity while maintaining
high sensitivity. Results will be imported in EndNote (ver-
sion X7.0.1, New York City: Thomson Reuters, 2011) and
duplicates will be removed. References will then be
exported to a Microsoft Excel (version 14.1.0, Redmond,
WA: Microsoft, 2011) spreadsheet in order to complete the
selection process.
Study selection
Two independent reviewers will screen all identified ref-
erences to determine eligibility, first from titles and ab-
stracts, and then based on full text evaluation for studies
that could be potentially eligible. In case of disagreement
on the inclusion of a study, a third reviewer will be con-
sulted. In case the blood product transfused is not
clearly specified, authors will be contacted to ensure that
reported data pertains to red blood cell transfusion.
A translation of non-English or non-French articles
will be obtained. Agreement on study selection will be
evaluated with a kappa coefficient. Considering the highsensitivity of the search strategy, we expect the kappa
will indicate moderate agreement. In case the agreement
is too low, indicating an evasive interpretation of eligibil-
ity criteria, a third reviewer will review records’ titles
and abstracts.
Data collection process
A preliminary version of the abstraction form will be
pilot-tested and customized by two reviewers using four
publications. Two independent reviewers will abstract
data using the standardized form. In case of discrepancy,
consensus will be reached with the involvement of a
third reviewer. Authors will be contacted if relevant data
is missing or clarification is needed.
Data items
Data pertaining to study characteristics (design, date of
completion, funding sources, and so on), patients’ baseline
characteristics (age, gender, type of neurological disease,
severity of the lesion on admission, and so on), clinical
management (surgical, medical), hemoglobin levels, blood
products (type of products received, timing, quantity, repe-
tition, thresholds, and so on), co-interventions (type,
timing), clinical outcomes (mortality and withdrawal of life-
sustaining therapies and their timing, length of hospital and
ICU stay, neurological outcome (any scale; for example,
Glasgow Outcome Score (GOS)), complications, and so on)
[Additional file 2] will be extracted from published reports.
Risk of bias in individual studies
Risk of bias of included RCTs will be assessed using The
Cochrane Collaboration tool for assessing the risk of bias
[22]. Risk of bias in cohort studies will be assessed using a
pilot version of a new tool for the assessment of the risk of
bias in non-randomized studies, currently under develop-
ment by Cochrane’s Non-Randomized Studies Methods
Group.
Summary measures
We will report the cumulative incidence of transfusion
in the course of hospital stay (primary outcome). Risk
ratios of the association between red blood cell transfu-
sion and potential determinants (categorical variables
such as sex) or any relevant clinical outcomes, such as
mortality, unfavorable neurological outcome, complica-
tions (any or specific complications, or categories of
complications [23]), will be reported. Mean differences
of potential determinants or outcomes (continuous or
ordinal variables such as age, hemoglobin levels, severity
of the traumatic brain injury, length of stay, and so on)
according to transfusion status will be reported. We will
compute mean transfusion thresholds as well as mean
differences in number of units transfused according to
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will be considered for all analyses.
Synthesis of results
If appropriate, results from cohort studies will be pooled
with results from randomized controlled trials that did
not randomize patients to specific transfusion strategies.
Results from randomized controlled trials allocating pa-
tients to different transfusion strategies will be pooled
separately, if deemed appropriate.
Variances of cumulative incidences of transfusion from
all studies will be stabilized using a Freeman-Tukey trans-
formation [24] and proportions will be pooled with DerSi-
monian and Laird random-effects approach [25] using R
statistical software (version 2.15.1: R Core Team, R Founda-
tion for Statistical Computing June 2012, Vienna, Austria).
Means and mean differences will be pooled with inverse
variance method with random effects. Risk ratio analyses
will be conducted with Review Manager (RevMan) (version
5.1, Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2012) using Mantel-Haenszel
random-effect models. Pooled effect sizes and their 95%
confidence limits will be reported.
Statistical heterogeneity will be measured using the
Cochran’s Q-test and I2 statistics [26], the latter being
interpreted as low from 0 to 40%, moderate from 30 to
60%, substantial from 50 to 90% and considerable from
75 to 100% [22].
Risk of bias
We will evaluate the risk of publication bias by visual ex-
ploration of funnel plots. We will also evaluate the risk
of selective reporting of outcomes within studies by
searching for previously published protocols on registra-
tion website (www.controlled-trials.com and clinical-
trials.gov).
The ability of a study to answer the review question
will be evaluated in terms of applicability. Applicability
concerns relate to deviation of a study from the ideal
study designed to answer our research question (in rela-
tion to our primary outcome). For instance, a study
recruiting patients with any severity of traumatic brain
injury at hospital admission, therefore including patients
with mild traumatic brain injury that might not be ad-




To assess the strength of observed associations, a priori
sensitivity analyses are planned to explore potential het-
erogeneity according to the following factors: severity of
the brain injury (moderate or severe traumatic brain in-
jury; severe only, defined as Glasgow Coma Scale (GCS) <9 or according), type of blood product given as a co-
intervention (platelets, plasma, whole blood, and so on),
risk of bias (low risk of bias), low applicability concerns,
design of studies (cohort versus randomized controlled
trials), presence of comorbidities (by categories of co-
morbidities [27] if data available) and year of publica-
tion (after 1999, year of the TRICC trial publication
[5]). A sensitivity analysis will also be conducted taking
into account if outcomes were reported as primary or
secondary outcomes.
Subgroup analyses
Subgroup analyses to assess clinical heterogeneity are
also planned to evaluate timing of intervention (emer-
gency, ICU, overall hospital stay or other timing), time
spent in the ICU or hospital, amount of blood trans-
fused, surgery or specific pharmacological interventions,
volume replacement, active bleeding and CRASH and
IMPACT scores.
Meta-regression
If the number of eligible studies is sufficient (at least ten
studies by covariate), we also plan on conducting a
meta-regression analysis; first, modeling mean values of
multiple determinants at study level with the reception
of a transfusion; secondly, transfusion and factors associ-
ated with mortality in traumatic brain injury (for example,
age and GCS) with mortality.
GRADE of evidences
We will use the GRADE methodology to evaluate the qual-




This project will allow the knowledge synthesis regard-
ing transfusion practices in patients with traumatic brain
injury. Considering the paucity of data and the equipoise
on the optimal transfusion strategy in this population, it
is of major importance to assess current practices.
Therefore, this project, in addition to our previous sys-
tematic review of comparative studies, will systematically
group original research data on the topic of red blood
cell transfusion in traumatic brain injury.
Inform future studies
Considering the observed lack of evidence from compara-
tive studies and the risk of bias associated with observa-
tional studies, we expect results to be heterogeneous. Our
results will provide information to inform the design of fur-
ther studies in traumatic brain injury and red blood cells
transfusion. Ultimately, we will obtain critical data regard-
ing transfusion practices in patients with traumatic brain
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inferiority trial. For example, information on the frequency
of transfusion among patients with traumatic brain injury
will facilitate the calculation of sample size estimates and
recruitment rates. The knowledge of the usual hemoglobin
thresholds observed in patients with traumatic brain injury
and those associated with better outcomes will help setting
acceptable, plausible and realistic comparative thresholds in
a future trial.
Limitations
Despite the use of rigorous methodology, we do expect
high statistical and clinical heterogeneity in our analyses
and few studies of low risk of bias. The strength of our con-
clusions may thus be limited by those factors. We may un-
cover only a limited number of comparative studies of
transfusion strategies that included a small number of pa-
tients. This may potentially limit the planned sensitivity and
subgroup analyses. In addition, we will conduct analysis of
potential determinants and outcomes associated with trans-
fusion through univariate analysis. In cohort studies, uni-
variate analyses of associations are prone to confusion bias.
If sufficient data are available, we will construct a meta-
regression, which will help to, at least partially, control for
potential confusion.
Little is known on optimal red blood cell transfusion
strategies in patients with traumatic brain injury. In order
to design studies to improve clinical practices, evidence-
based information has to be gathered. We propose to con-
duct a systematic review that will synthesize the current
knowledge from published clinical studies in the field. Our
results will be used to optimize future prospective studies
on this topic in order to conduct high-quality and rigorous
studies with the aim of increasing the quality of care re-
ceived by patients with traumatic brain injury.
Additional files
Additional file 1: Search strategy for MEDLINE/PubMed.
Additional file 2: Outcome variables.
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